Participant selection for preventive Regenerative Medicine trials: ethical challenges of selecting individuals at risk

Journal of Medical Ethics
S L NiemansburgA L Bredenoord

Abstract

The innovative field of Regenerative Medicine (RM) is expected to extend the possibilities of prevention or early treatment in healthcare. Increasingly, clinical trials will be developed for people at risk of disease to investigate these RM interventions. These individuals at risk are characterised by their susceptibility for developing clinically manifest disease in future due to the existence of degenerative abnormalities. So far, there has been little debate about the ethical appropriateness of including such individuals at risk in clinical trials. We discuss three main challenges of selecting this participant model for testing RM interventions: the challenge of achieving a proportional risk-benefit balance; complexities in the trial design in terms of follow-up and sample size; and the difficulty of obtaining informed consent due to the many uncertainties. We conclude that selecting the model is not ethically justifiable for first-in-man trials with RM interventions due to the high risks and uncertainties. However, the model can be ethically appropriate for testing the efficacy of RM interventions under the following conditions: interventions should be low risk; the degenerative abnormalities (and other risk factors) should...Continue Reading

References

Feb 24, 2001·Science·U HoffrageG Gigerenzer
Apr 6, 2002·BMJ : British Medical Journal·Adrian EdwardsAl Mulley
Mar 18, 2004·Critical Care : the Official Journal of the Critical Care Forum·Charles Weijer
Jul 11, 2006·The Journal of Pediatrics·Lainie Ross
Oct 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jonathan Kimmelman
Nov 1, 2007·Journal of Medical Ethics·S Matthew LiaoUNKNOWN Working Group on Ethics of Progenitor Cell-based Strategies for Disease Prevention
Jan 5, 2008·Medical Law Review·Pamela R Ferguson
Sep 2, 2008·Journal of Medical Ethics·L TrommelmansK Dierickx
Feb 28, 2009·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Rebecca Dresser
May 29, 2010·Kennedy Institute of Ethics Journal·James A Anderson, Jonathan Kimmelman
Jul 8, 2010·Journal of Human Reproductive Sciences·Priya SelvarajKalaichelvi Srinivasan
Mar 23, 2011·PLoS Medicine·Jonathan Kimmelman, Alex John London
Jun 20, 2012·Statistics in Medicine·Thomas R Fleming, John H Powers
Dec 25, 2012·Regenerative Medicine·Sophie L NiemansburgAnnelien L Bredenoord
Jan 8, 2013·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Rebecca Dresser
Aug 21, 2013·Journal of the American College of Cardiology·Gianluigi SavaresePasquale Perrone-Filardi
Apr 16, 2014·The American Journal of Bioethics : AJOB·S L NiemansburgA L Bredenoord

❮ Previous
Next ❯

Citations

Nov 30, 2018·Journal of Empirical Research on Human Research Ethics : JERHRE·Farirai MutenherwaTulio de Oliveira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Tissue Engineering. Part a
S L NiemansburgA L Bredenoord
European Journal of Clinical Pharmacology
D G Grahame-Smith
Journal of General Internal Medicine
P A Lecso
The Spine Journal : Official Journal of the North American Spine Society
S L NiemansburgA L Bredenoord
© 2021 Meta ULC. All rights reserved